A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

Panelist discusses how CA 19-9 serves as a useful tumor marker for disease monitoring and recurrence detection in patients ...

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising ...

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.

Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.